Fosamax Plus D

Fosamax Plus D is a brand name of alendronate/cholecalciferol, approved by the FDA in the following formulation(s):

FOSAMAX PLUS D (alendronate sodium; cholecalciferol - tablet; oral)

• 
  Manufacturer: MERCK
  
  Approval date: April 7, 2005
  
  Strength(s): EQ 70MG BASE;2,800 IU
  


• 
  Manufacturer: MERCK
  
  Approval date: April 26, 2007
  
  Strength(s): EQ 70MG BASE;5,600 IU ^[RLD]

Has a generic version of Fosamax Plus D been approved?

No. There is currently no therapeutically equivalent version of Fosamax Plus D available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fosamax Plus D. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Dry mix formulation for bisphosphonic acids with lactose
  Patent 5,358,941
  Issued: October 25, 1994
  Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
  Assignee(s): Merck & Co., Inc.
  Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
  
  Patent expiration dates:
  
  
  • December 2, 2012
    
    ✓ 
    Drug product
  
  
  
  • June 2, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dry mix formulation for bisphosphonic acids
  Patent 5,681,590
  Issued: October 28, 1997
  Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
  Assignee(s): Merck & Co., Inc.
  Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
  
  Patent expiration dates:
  
  
  • December 2, 2012
    
    ✓ 
    Drug product
  
  
  
  • June 2, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for inhibiting bone resorption
  Patent 5,994,329
  Issued: November 30, 1999
  Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
  Assignee(s): Merck & Co., Inc.
  Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
  
  Patent expiration dates:
  
  
  • July 17, 2018
    
    ✓ 
    Patent use: TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • January 17, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dry mix formulation for bisphosphonic acids
  Patent 6,090,410
  Issued: July 18, 2000
  Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
  Assignee(s): Merck & Co., Inc.
  Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
  
  Patent expiration dates:
  
  
  • December 2, 2012
    
    ✓ 
    Drug product
  
  
  
  • June 2, 2013
    
    ✓ 
    Pediatric exclusivity
    ✓ 
    Drug product
  
  

See also...

• Fosamax Plus D Consumer Information (Drugs.com)
• Fosamax Plus D Consumer Information (Wolters Kluwer)
• Fosamax Plus D Consumer Information (Cerner Multum)
• Fosamax Plus D Advanced Consumer Information (Micromedex)
• Alendronate/Cholecalciferol Consumer Information (Wolters Kluwer)
• Alendronate and cholecalciferol Consumer Information (Cerner Multum)
• Alendronate and cholecalciferol Advanced Consumer Information (Micromedex)